Lisa A. Porter

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Daniel J. Drucker, John B. Buse, Kristin Taylor et al. · The Lancet · 2008 · 1.1K citations

Non-pharmacological Intervention, Diabetes Management, Insulin Management +7

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

James R. Berenson, Alan Lichtenstein, Lisa A. Porter et al. · Journal of Clinical Oncology · 1998 · 652 citations

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

John B. Buse, Michael A. Nauck, Thomas Först et al. · The Lancet · 2012 · 559 citations

Diabetes Management, Diabetes, Type 2 +5

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

Thomas Blevins, John Pullman, Jaret Malloy et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 442 citations · Full text

Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer

Nisha Anand, Sabita K. Murthy, Gudrun Amann et al. · Nature Genetics · 2002 · 266 citations

Medicine, Putative Oncogene, Cancer Genetics +5